Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Average PT from Brokerages
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […]
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […]
